fda semaglutide news 🎉Exciting that is now approved for MASH (aka fatty liver disease) “At week 72, the primary efficacy endpoint was based on histology (liver biopsy results). Interim results showed 63% U.S. FDA finds no evidence

In the obesity trials, participants on the 12 mg dose reached up to roughly 2829% mean body-weight reduction at 68 to 80 weeks, with a large share crossing the 25% and 30% thresholds, the strongest weight result reported for a GLP-1-class compound in a phase 3 trial [5]

Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes 2019

GLP-1 medications like Ozempic, Wegovy, and Mounjaro have become almost impossible to escape

Common side effects are much more likely to include mild nausea, constipation, or indigestion, which are generally manageable and tend to improve over time as your body adjusts

Stress-Free Commuter Access: Skip the gridlock and expensive parking of downtown metropolitan networks

Therefore, these data have delays and often require a patient encounter to have occurred prior to being ingested